EMEA-002475-PIP02-19-M02

Key facts

Active substance
Spesolimab
Therapeutic area
Dermatology
Decision number
P/0049/2022
PIP number
EMEA-002475-PIP02-19-M02
Pharmaceutical form(s)
  • Solution for infusion
  • Solution for injection
Condition(s) / indication(s)
  • Prevention of generalized pustular psoriasis
  • Treatment of generalized pustular psoriasis
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries
Boehringer Ingelheim International GmbH

Tel. +49 6132 778271
Email: Paediatrics@boehringer-ingelheim.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating